All In Biotech

Drug Trial Radar · NCT05100225

Efficacy and Safety Trial of PTP-001 (MOTYS) for Symptomatic Knee Osteoarthritis

A Multiple Arm, Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase 2 Study of Intra-Articular Administration of an Allogeneic Human Placental Tissue Particulate (PTP-001) for the Treatment of Knee Osteoarthritis

Last checked: Nov 19, 2026Latest source record: Jul 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 210 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

210

Planned (sponsor's estimate)

Start

Sep 30, 2021

Primary completion

Oct 31, 2022

Study completion Nov 30, 2022

Sponsor

Lead sponsor
Bioventus LLCIndustry
Sponsor type
Industry
Collaborators
NBCD A/S
First posted
Oct 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluation of safety, tolerability and efficacy of a single intra-articular (IA) injection of PTP-001, an allogeneic placental tissue particulate, in individuals with knee osteoarthritis (OA).

Conditions

  • Osteoarthritis, Knee

Interventions

  • PTP-001Biological

    Allogeneic human placental tissue particulate (PTP-001) is administered as a single intra-articular injection to the target knee after resuspension with saline.

  • Placebo controlOther

    The placebo control, physiological saline (0.9% sodium chloride injection, USP), is administered as an intra-articular injection to the target knee.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy - Change from pretreatment baseline in the WOMAC pain subscaleTime frame: At 6 months
  2. Safety - Incidence of local and systemic AEsTime frame: Over 6 months

Locations

14 sites in 3 countries. Site status is shown where the registry gives one.

  • Emeritus Research Sydney

    Botany, New South Wales, Australia

  • Genesis Research Services

    Broadmeadow, New South Wales, Australia

  • Royal North Shore Hospital

    Saint Leonards, New South Wales, Australia

  • Holdsworth House Medical Practice

    Sydney, New South Wales, Australia

  • Emeritus Research Melbourne

    Camberwell, Victoria, Australia

  • Hamilton Medical Research Group

    Hamilton, Ontario, Canada

  • McMaster University Department of Surgery St. Joseph's Healthcare Hamilton

    Hamilton, Ontario, Canada

  • Canadian Phase Onward Inc.

    Toronto, Ontario, Canada

  • Diex Recherche Quebec Inc.

    Québec, Quebec, Canada

  • Centrede Recherche Saint-Louis

    Québec, Quebec, Canada

  • Diex Recherche Sherbrooke Inc.

    Sherbrooke, Quebec, Canada

  • Sanos Clinic Nordjylland

    Gandrup, Denmark

  • Sanos Clinic

    Herlev, Denmark

  • Sanos Clinic Syddanmark

    Vejle, Denmark

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.